The exclusive rights for reverse transfection allow us to further invest in our mission, which is to improve human health by empowering companies and organizations to discover cures faster.
Boston, Massachusetts (PRWEB) April 08, 2016
Persomics AB and Whitehead Institute sign exclusive license agreement, making Persomics sole rightsholder to reverse transfection.
The method, accessible through Persomics’ innovative technology, is a powerful platform for drug discovery. It is also a foundation for current and future technologies and innovations for Persomics. Together with the recent grant of key patents in the Persomics portfolio this has helped build remarkable momentum for the company.
Persomics is currently offering RNAi-based applications as a tailored product to pharmaceutical companies and academic labs. In a move to further increase the accessibility of phenotypic screening, a number of new tools using reverse transfection will be offered as off-the-shelf-products starting Q3 2016.
“The exclusive rights for reverse transfection allow us to further invest in our mission, which is to improve human health by empowering companies and organizations to discover cures faster”, says Dr. Neil Emans, CEO of Persomics USA. “By using Persomics technology, researchers investigating the function of the human genome are no longer limited by cost, and are empowered by increased access to cutting-edge technology.”
The reverse transfection method was reported by David Sabatini and his colleagues at Whitehead Institute in 2001. The core method consists of printing small amounts of expression constructs with a polymer and transfection reagent onto a slide. This creates a miniaturized array of individual, distinct experiments where overlaid cells are transfected on the printed spot.
Whitehead Institute is a world-renowned non-profit research institution dedicated to improving human health through basic biomedical research. Wholly independent in its governance, finances, and research programs, Whitehead shares a close affiliation with Massachusetts Institute of Technology through its faculty, who hold joint MIT appointments.
Persomics provides ImagineArrays™, a technology that miniaturizes, accelerates and increases the scale of phenotypic screening. Researchers investigating the function of the human genome and disease are no longer limited by automation requirements or cost, but by their need to discover more. With Persomics this can be achieved at a fraction of the investment required in large industrial research labs. With our technology the science can go further, faster.